Here, we describe the testing of the combination of roflumilast (Ro) with R-CHOP (Ro+R-CHOP) in a pilot cohort of treatment-naïve patients with DLBCL of non-GCB (germinal center B-cell like) origin. Here, DDIT3 is linked to diffuse large B-cell lymphoma.